Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074581 · ClinicalTrials.gov registry record · Phase 3
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,526
- Enrollment target
NCT00074581: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00074581 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,526 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (357% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00074581, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,526 participants
- Enrollment target
Study Summary
This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
Primary Outcome
incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm. Only acquisition from the index partner were included in the primary analysis, therefore, each endpoint was required to be confirmed (by genotyping) such that the viral envelop sequence in the index case matched that of the partner.
Interventions
- DRUG Lamivudine
- DRUG Atazanavir
- DRUG Efavirenz
- DRUG Didanosine
- DRUG Emtricitabine/Tenofovir disoproxil fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,526 participants |
| Start Date | 2005-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
What the finished NCT00074581 record still lists
NCT00074581 is an interventional study that assigns participants to a tested intervention. Its 3,526 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (357% higher).
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00074581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00074581 about?
NCT00074581 is a clinical study titled "Preventing Sexual Transmission of HIV With Anti-HIV Drugs". This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
What is the current status of trial NCT00074581?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,526 participants. The study started on 2005-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00074581?
The interventions under investigation include: Lamivudine (DRUG), Atazanavir (DRUG), Efavirenz (DRUG), Didanosine (DRUG), Emtricitabine/Tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT00074581?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00074581's enrollment target sits among peer trials
3,526 68th of 2000 higher than 1,933 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia